Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur. Urol. (2023)].
Eur Urol
; 84(5): e123-e124, 2023 Nov.
Article
in En
| MEDLINE
| ID: mdl-37666734
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Eur Urol
Year:
2023
Document type:
Article
Country of publication:
Switzerland